Glaukos® iStent Infinite Trabecular Micro-Bypass System in Subjects With Mild to Moderate Primary Open-angle Glaucoma
Recruiting
A Prospective, Multicenter Study of the Glaukos® iStent Infinite Trabecular Micro-Bypass System Model iS3 in Subjects With Mild to Moderate Primary Open-angle Glaucoma
Who can join
Ages 35 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Diagnosis of primary open-angle glaucoma * Phakic or pseudophakic * Age 35 years or older Exclusion Criteria: * Traumatic, uveitic, neovascular, angle-closure glaucoma or * glaucoma associated with vascular disorders * Active corneal inflammation or edema * Retinal disorders not associated with glaucoma
About the study
Prospective, multicenter, single-arm study of the iStent infinite in adult pseudophakic or phakic subjects with mild to moderate primary open angle glaucoma who have not failed conventional medical and surgical treatment
What is being tested
- iStent Infinite (device)
Sponsor: Glaukos Corporation · Participants: 245 · Started: Sep 1, 2023
Contact the study team
- Dari Parizadeh · Phone: 949-481-0575
- Kerry Stephens · Phone: 949-481-8057
Official record on ClinicalTrials.gov — NCT06057051
Locations in the U.S.
| Ohio | Glaukos Investigator Site, Cincinnati |
Conditions
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.